Navigation Links
FDA Accepts Aricept® Patch (Donepezil Transdermal System) NDA for Review
Date:9/17/2010

SAN JOSE, Calif., Sept. 17 /PRNewswire/ -- Teikoku Pharma USA, Inc., an international specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for a new weekly transdermal patch of Aricept®, a leading medication for the treatment of Alzheimer's disease.

The company developed the weekly Aricept(r) patch based on a license agreement executed between Teikoku Pharma USA, Inc. and Eisai Co., Ltd. (Eisai) in February 2009. The acceptance of the NDA indicates that the FDA deems the company's submission to be sufficient to review. The NDA was submitted to the FDA by Teikoku Pharma USA, Inc. on June 30, 2010. If approved, Eisai's subsidiary, Eisai Inc., will hold marketing rights in the U.S.

The Aricept® transdermal patch formulation employs a unique drug delivery system, making it the world's first weekly transdermal patch for the treatment of Alzheimer's disease. It was developed to provide a potential new treatment option to Alzheimer's disease patients who have trouble swallowing, as well as to reduce the burden on caregivers and family members who administer medication to patients.

About Teikoku

Teikoku Pharma USA, Inc., a wholly-owned subsidiary of Teikoku Seiyaku Co., Ltd. that is a leading supplier of the topical analgesic transdermal patch, Lidoderm®, in the world, is a specialty pharmaceutical company that develops and manufactures enhanced pharmaceutical products with its transdermal drug delivery technology. Teikoku focuses its efforts on two therapeutic areas: chronic and acute pain, and the central nervous system (CNS). The company looks forward to exploring a new field of CNS with the systemic transdermal patch.  Teikoku is committed to applying its transdermal technology for the benefit of patients and partners. For more information, please visit www.teikokuusa.com.

About Eisai

Eisai Co., Ltd. is a research-based human health care (hhc) company that discovered and developed Aricept® (Donepezil HCl tablets), the number-one prescribed Alzheimer's medication worldwide. It is sold in approximately 75 countries. In the United States, the product is co-promoted by Eisai Inc. and Pfizer Inc. and distributed by Eisai Inc. Aricept® continues to be studied for various potential new indications and formulations. Eisai focuses its efforts on three therapeutic areas: integrative neuroscience, integrative oncology, and vascular and immunology reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. For more information, please visit www.eisai.co.jp.


'/>"/>
SOURCE Teikoku Pharma USA, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Accepts Sanofi Pasteur File Submission for Novel Influenza Vaccine Delivered by Intradermal Microinjection
2. FDA Accepts Sanofi Pasteurs Application to Expand Indication of Menactra® Vaccine to Infants and Toddlers
3. Talecris Biotherapeutics CEO Accepts 2010 Ernst & Young Entrepreneur Of The Year Award on Behalf of Employees and Patients
4. FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review
5. FDA Accepts sNDA for Alternative Dosing Regimen for Dacogen(R) (decitabine for injection) to Treat Patients with Myelodysplastic Syndromes (MDS)
6. FDA Accepts Arno Therapeutics IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway
7. Food and Drug Administration Accepts Isolagens Biologics License Application for Full Review
8. FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)
9. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
10. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
11. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017  Zimmer Biomet Holdings, ... musculoskeletal healthcare, today announced that it will be participating ... Conference at the InterContinental Hotel in Boston, ... Biomet will present at 11:20 a.m. Eastern Time. ... accessed via Zimmer Biomet,s Investor Relations website at ...
(Date:4/20/2017)... April 20, 2017  CVS Pharmacy, the retail ... a new store design to enhance the retail ... food, health-focused products and expanded beauty selections paired ... customers discover new offerings. Together with its innovative ... of the customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... , April 20, 2017 ... platform, the first non-viral gene expression technology that enables ... the eye to address a wide range of ophthalmic ... Medicines and Healthcare products Regulatory Agency (MHRA) to advance ... ...
Breaking Medicine Technology:
(Date:4/24/2017)... McLean, Virginia (PRWEB) , ... April 24, 2017 ... ... have announced that they are seeking public support to bring their novel lifesaving ... in appearance, wearable device packed with medical-grade sensors, specially designed to read a ...
(Date:4/24/2017)... ... April 24, 2017 , ... symplrTM, a leading provider of ... that Kyle Allain has joined the company as Vice President and General Manager ... provider, payor and managed care solutions. , A seasoned executive with more ...
(Date:4/24/2017)... ... April 24, 2017 , ... MAP Health ... anxiety levels in people with addiction who are served by MAP’s patient engagement ... wearable device that monitors heart and breath rates to identify anxiety levels and ...
(Date:4/24/2017)... ... April 24, 2017 , ... As a former supermodel ... thousand words. The good news for single women is that she put all the ... available on April 25th. Joan's insight, personal experiences and sparkling sense of humor have ...
(Date:4/24/2017)... ... April 24, 2017 , ... Donna Parker, L. Ac. reads all sorts of ... of them to be very practical. She wanted to write a guide/workbook that would ... their health. It prompted her in writing “ A Clear Path to a Vibrant ...
Breaking Medicine News(10 mins):